FDA
-
-
-
-
-
-
-
Avinger (AVGR) Increases Focus on Coronary Development, Cuts Costs
-
-
-
-
-
-
-
Avinger Reports First Quarter 2023 Results
-
-
-
-
-
-
-
Avinger Reports Third Quarter 2022 Results
-
-
-
-
-
-
-
Avinger Reports Fourth Quarter and Year End 2021 Results
-
-
-
-
-
-
-
Avinger (AVGR) Announces FDA Clearance of Pantheris for the Treatment of In-Stent Restenosis
-
-
-
-
-
-
-
Pre-Open Stock Movers 06/29: (CERE) (CNSP) (VERB) Higher; (DMAC) (CELC) (ALGS) Lower (more...)
-
-
-
-
-
-
-
Avinger Announces 510(k) Filing of Ocelaris Next Generation Image-guided CTO Crossing System
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

